Pantoprazole | CAS#102625-70-7 | proton pump inhibitor

MedKoo Cat#: 585064 | Name: Pantoprazole

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pantoprazole is a 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of gastroesophageal reflux and peptic ulcer. Treatment of conditions with Pantoprazole has raised concern about its inappropriate and overuse, both in children and adults.

Chemical Structure

Pantoprazole

CAS#102625-70-7

Theoretical Analysis

MedKoo Cat#: 585064

Name: Pantoprazole

CAS#: 102625-70-7

Chemical Formula: C16H15F2N3O4S

Exact Mass: 383.0751

Molecular Weight: 383.37

Elemental Analysis: C, 50.13; H, 3.94; F, 9.91; N, 10.96; O, 16.69; S, 8.36

Price and Availability

Size	Price	Availability
250mg	USD 400.00	2 Weeks
500mg	USD 600.00	2 Weeks
1g	USD 900.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Pantoprazole; BY 1023; BY-1023; SK&F 96022; SK&F-96022

IUPAC/Chemical Name

1H-Benzimidazole, 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-

InChi Key

IQPSEEYGBUAQFF-UHFFFAOYSA-N

InChi Code

InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)

SMILES Code

O=S(C1=NC2=CC(OC(F)F)=CC=C2N1)CC3=NC=CC(OC)=C3OC

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI).

In vitro activity:

The present study investigated the effects of pantoprazole (PPZ) treatment and PKM2 transfection on human gastric adenocarcinoma SGC-7901 cells in vitro. The present study revealed that PPZ inhibited the proliferation of tumor cells, induced apoptosis and downregulated the expression of PKM2, which contributes to the current understanding of the functional association between PPZ and PKM2. Reference: Oncol Lett. 2016 Jan;11(1):717-722. https://pubmed.ncbi.nlm.nih.gov/26870273/

In vivo activity:

Pantoprazole (0.3-3 mg/kg, p.o.) as well as omeprazole (1-10 mg/kg, p.o.) and lansoprazole (1-10 mg/kg, p.o.) dose-dependently decreased both basal acid secretion in pylorus-ligated rats and the stimulated acid secretion induced by mepirizole in acute fistula rats, and the effects of pantoprazole were more potent than those of omeprazole and lansoprazole, the ED50 values for the stimulated acid secretion being 0.8, 2.0 and 1.2 mg/kg, respectively. Reference: J Gastroenterol Hepatol. 1999 Mar;14(3):251-7. https://pubmed.ncbi.nlm.nih.gov/10197495/

	Solvent	mg/mL	mM
Solubility
	DMF	30.0	78.25
	DMSO	53.0	138.25
	DMSO:PBS (pH 7.2) (1:1)	0.5	1.30
	Ethanol	40.5	105.64

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 383.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Zeng X, Liu L, Zheng M, Sun H, Xiao J, Lu T, Huang G, Chen P, Zhang J, Zhu F, Li H, Duan Q. Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase. Oncotarget. 2016 Apr 19;7(16):22460-73. doi: 10.18632/oncotarget.7984. PMID: 26967058; PMCID: PMC5008373. 2. Shen Y, Chen M, Huang S, Zou X. Pantoprazole inhibits human gastric adenocarcinoma SGC-7901 cells by downregulating the expression of pyruvate kinase M2. Oncol Lett. 2016 Jan;11(1):717-722. doi: 10.3892/ol.2015.3912. Epub 2015 Nov 13. PMID: 26870273; PMCID: PMC4727057. 3. Histing T, Stenger D, Scheuer C, Metzger W, Garcia P, Holstein JH, Klein M, Pohlemann T, Menger MD. Pantoprazole, a proton pump inhibitor, delays fracture healing in mice. Calcif Tissue Int. 2012 Jun;90(6):507-14. doi: 10.1007/s00223-012-9601-x. Epub 2012 Apr 24. PMID: 22527206. 4. Takeuchi K, Konaka A, Nishijima M, Kato S, Yasuhiro T. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. J Gastroenterol Hepatol. 1999 Mar;14(3):251-7. doi: 10.1046/j.1440-1746.1999.01843.x. PMID: 10197495.

In vitro protocol:

In vivo protocol:

1. Histing T, Stenger D, Scheuer C, Metzger W, Garcia P, Holstein JH, Klein M, Pohlemann T, Menger MD. Pantoprazole, a proton pump inhibitor, delays fracture healing in mice. Calcif Tissue Int. 2012 Jun;90(6):507-14. doi: 10.1007/s00223-012-9601-x. Epub 2012 Apr 24. PMID: 22527206. 2. Takeuchi K, Konaka A, Nishijima M, Kato S, Yasuhiro T. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. J Gastroenterol Hepatol. 1999 Mar;14(3):251-7. doi: 10.1046/j.1440-1746.1999.01843.x. PMID: 10197495.

1: Liu H. Association between PCSK9 inhibitors and acute kidney injury: a pharmacovigilance study. Front Pharmacol. 2024 Aug 1;15:1353848. doi: 10.3389/fphar.2024.1353848. PMID: 39148544; PMCID: PMC11324468. 2: Nobre AFD, Sousa AMS, Costa ADC, Fernandes MR, Kumar R, Ponne S, Rocha MG, Rodrigues AM, Camargo ZP, Brilhante RSN. Effect of proton pump inhibitors on susceptibility and melanogenesis of Sporothrix species. J Med Microbiol. 2024 Aug;73(8). doi: 10.1099/jmm.0.001870. PMID: 39145374. 3: Kim JS, Kim BW, Kim JI, Chung WC, Jung SW, Bang CS, Kim GH, Jeon SW, Joo MK, Lee SH, Lim YJ, Sung JK, Seo SY, Park SY, Lee WS, Lee HL, Kim KB, Kim HU. Empirical Therapy Versus Tailored Therapy of Helicobacter pylori in Korea: Results of the K-CREATE Study. Helicobacter. 2024 Jul-Aug;29(4):e13126. doi: 10.1111/hel.13126. PMID: 39143948. 4: Rovatti I, Di Girolamo N, Scarabelli S. Addition of a metoclopramide constant rate infusion to prevent ptyalism, regurgitation and vomiting in brachycephalic dogs undergoing spinal surgery. Vet Anaesth Analg. 2024 Jul 11:S1467-2987(24)00128-4. doi: 10.1016/j.vaa.2024.07.004. Epub ahead of print. PMID: 39142985. 5: Zhu JD, Yang LJ, Zhao JN, Wang P, Li YH, Zhang XS, Pan JM, Jiang MH, Yang HY, Yin SJ, He GH. Short-term usage of proton pump inhibitors during admission was associated with increased risk of rehospitalization in critically ill patients with myocardial infarction: a cohort study. Eur J Clin Pharmacol. 2024 Aug 14. doi: 10.1007/s00228-024-03737-y. Epub ahead of print. PMID: 39141126. 6: Prakash MD, T LN, Joy L. Reflux Finding Score and Reflux Symptom Index Potential Indicators for Diagnosis and Management of Laryngopharyngeal Reflux Disease. Indian J Otolaryngol Head Neck Surg. 2024 Aug;76(4):3239-3244. doi: 10.1007/s12070-024-04657-0. Epub 2024 Apr 20. PMID: 39130302; PMCID: PMC11306491. 7: Sebastian A, Bhaskar E, Moorthy S, M L. Reversible Second-Degree Heart Block Attributed to Ondansetron: A Rare Side Effect. Cureus. 2024 Jul 8;16(7):e64109. doi: 10.7759/cureus.64109. PMID: 39119392; PMCID: PMC11306193. 8: Ai MY, Chen YZ, Kuo CL, Chang WL. A network meta-analysis: evaluating the efficacy and safety of concurrent proton pump inhibitors and clopidogrel therapy in post-PCI patients. Front Cardiovasc Med. 2024 Jul 24;11:1385318. doi: 10.3389/fcvm.2024.1385318. PMID: 39114562; PMCID: PMC11303300. 9: Krishnan M, Fernando H, Mohammed HH, Vithanage N. Proton Pump Inhibitor Induced Hypomagnesemia Causing Seizures: A Rare Adverse Effect of a Commonly Used Medication. Cureus. 2024 Jul 7;16(7):e64044. doi: 10.7759/cureus.64044. PMID: 39114244; PMCID: PMC11303836. 10: Jiang H, Bu X, Liu T, Jiang B. Oculomotor nerve palsy caused by imidacloprid at initial diagnosis: A case report. Medicine (Baltimore). 2024 Aug 2;103(31):e39160. doi: 10.1097/MD.0000000000039160. PMID: 39093779; PMCID: PMC11296451. 11: Baptista A, Marreiros A, Macedo A, Coelho A. Drug-Associated Acute Kidney Disease: Data From a World Pharmacovigilance Database. Cureus. 2024 Jul 1;16(7):e63636. doi: 10.7759/cureus.63636. PMID: 39092339; PMCID: PMC11292151. 12: Alfaris H, Sit M, Johnson SR. Scleritis in Systemic Sclerosis Treated With Infliximab Biosimilar. J Rheumatol. 2024 Aug 1:jrheum.2024-0496. doi: 10.3899/jrheum.2024-0496. Epub ahead of print. PMID: 39089825. 13: Wu B, Xiao M, Wu F, Xu T. Signal of dementia with proton pump inhibitor after minimizing competition bias: an updated disproportionality analysis. Expert Opin Drug Saf. 2024 Aug 5:1-8. doi: 10.1080/14740338.2024.2387314. Epub ahead of print. PMID: 39082094. 14: Ang SP, Chia JE, Valladares C, Patel S, Gewirtz D, Iglesias J. Association between Proton Pump Inhibitor Use and Risk of Incident Chronic Kidney Disease: Systematic Review and Meta-Analysis. Biomedicines. 2024 Jun 25;12(7):1414. doi: 10.3390/biomedicines12071414. PMID: 39061988; PMCID: PMC11274577. 15: Levinson RT, Paul C, Meid AD, Schultz JH, Wild B. Identifying Predictors of Heart Failure Readmission in Patients From a Statutory Health Insurance Database: Retrospective Machine Learning Study. JMIR Cardio. 2024 Jul 23;8:e54994. doi: 10.2196/54994. PMID: 39042456; PMCID: PMC11318205. 16: Li W, Yu Y, Li M, Fang Q, Jin X, Lin H, Xu J. Identification of novel signal of proton pump inhibitor-associated drug reaction with eosinophilia and systemic symptoms: a disproportionality analysis. Int J Clin Pharm. 2024 Jul 23. doi: 10.1007/s11096-024-01778-y. Epub ahead of print. PMID: 39042351. 17: Prabhoo RY, Pai UA, Wadhwa A, Pillai BV, D'souza C, Wadhawan M, Bhatnagar M, Prabhoo MR, Shetty S, Seshadri VP, Bhatnagar S, Manchanda SC, Kher V. Multidisciplinary Consensus for Rationalizing the Use of Acid Suppressants in Children and Adults: CONFOR. Euroasian J Hepatogastroenterol. 2024 Jan- Jun;14(1):99-119. doi: 10.5005/jp-journals-10018-1430. PMID: 39022200; PMCID: PMC11249898. 18: Upadhyay R, Soni NK, Kotamkar AA, Naseem A, Phadke A, Nayar S, Pallewar S, Shetty P, Mungantiwar A, Jaiswal S, Qamra A. High Dose Pantoprazole for Gastroesophageal Reflux Disease: Need, Evidence, Guidelines and Our Experience. Euroasian J Hepatogastroenterol. 2024 Jan-Jun;14(1):86-91. doi: 10.5005/jp- journals-10018-1426. PMID: 39022196; PMCID: PMC11249892. 19: Choudhary R, Khan MA, Dosi R, Choudhari S, Pawar D, Shahavi V, Sharma A. Fixed dose combination of aspirin and pantoprazole: Results of a multicenter, comparative, randomized, double-blind, double dummy, phase III study in Indian patients. Indian Heart J. 2024 Jul 14:S0019-4832(24)00160-3. doi: 10.1016/j.ihj.2024.07.007. Epub ahead of print. PMID: 39009075. 20: Entezari B, Akbaba H, Gurer-Orhan H. Modulation of adipogenesis and lipogenesis by indomethacin and pantoprazole. Toxicol In Vitro. 2024 Jul 14;100:105895. doi: 10.1016/j.tiv.2024.105895. Epub ahead of print. PMID: 39004236.